MindBio Reports Sustained Antidepressant Effects from Microdosing LSD in Phase 2A Depression Trials

LOS ANGELES- MindBio Therapeutics Corp. a Vancouver-based biopharmaceutical company, has announced promising durability data from its Phase 2A clinical trials testing MB22001, a proprietary microdosed LSD treatment for depression. The study, which involved self-administered, take-home microdoses, showed that patients experienced a 62.8% reduction in depressive symptoms three months after completing an 8-week course.

The Phase 2A trial demonstrated a strong safety, adherence, and tolerance profile, aligning with results from earlier Phase 1 trials. The findings support MindBio’s strategy of using low-dose, non-hallucinogenic psychedelic therapies for community-based treatment, distinguishing it from the more common high-dose clinic-based therapies in the psychedelic sector.

MindBio is currently the only organization conducting multiple Phase 2B trials with regulatory approval for at-home use of a psychedelic medication. The company’s approach aims to offer an affordable and scalable alternative to the traditional, resource-intensive clinic-based treatments. Ongoing trials include studies in depression, cancer-related distress, and pre-menstrual syndromes, with the trials fully funded and expected to run through 2025.

CEO Justin Hanka highlighted the significance of the sustained antidepressant response, noting its positive implications for MindBio’s current Phase 2B trials in depression and cancer. The results underscore the potential of microdosing as a viable treatment for depression and other mental health conditions. The company’s scientific manuscript detailing the findings has been submitted to the British Journal of Psychiatry for peer review.

As the trials progress, MindBio’s focus on take-home microdosing therapies could position it as a leader in the growing field of psychedelic medicine, offering new treatment pathways for patients with limited access to traditional therapies.